�鶹��Ƶ

PlaqueTec and Babraham �鶹��Ƶ collaboration advances drug identification for heart disease treatment

A project uniting PlaqueTec’s innovation in precision-medicine for coronary artery disease (CAD) and expertise from the Welch lab at �鶹��Ƶ has demonstrated the ‘drugability’ of a pro-inflammatory protein discovered by PlaqueTec.

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), worked with Dr Heidi Welch and her research group to test the pro-inflammatory protein in a human cell culture model, demonstrating its potential to be targeted by small molecule drugs— opening up new opportunities for a precision medicine approach to heart disease. The target is now being evaluated as part of PlaqueTec’s and, if validated, further development will be pursued.

Dr Simon Williams, General Manager, PlaqueTec, commented: “The successful completion of our latest collaboration with �鶹��Ƶ is an encouraging demonstration that new disease-specific targets identified by PlaqueTec have the potential to be modifiable by small molecule drugs. As we continue our BIOPATTERN trial, we are confident that our unique approach to endotyping CAD will pave the way for a new era of precision medicine for millions of patients with the disease.”

Dr Heidi Welch, Associate Group Leader, Signalling Research Programme at �鶹��Ƶ, added: “Our work is focused on the molecular mechanisms that control a specific family of proteins, particularly in inflammatory cells, and we are delighted to have leveraged this expertise in an early phase target discovery and development project with PlaqueTec for its recently discovered pro-inflammatory protein target. Following the success of this collaboration, we are excited to see this novel drug target undergo further evaluation in PlaqueTec’s BIOPATTERN trial.”

PlaqueTec, based at the Babraham Research Campus, and the Welch research group were supported by a UKRI-BBSRC Campus Innovation Award (CIA), via the Babraham Research Campus Collaboration Fund in October 2023.

In February 2022, PlaqueTec was awarded Innovate UK Business Growth funding to collaborate with to work on a aimed at identifying novel drug targets in CAD. Data obtained from this earlier project formed the basis for the CIA-funded project to evaluate lead compounds against one of the targets identified.

Derek Jones, Chief Executive of Babraham Research Campus, said: "The UKRI-BBSRC Campus Innovation Award was initiated last year to give individuals and companies on Campus access to a unique tranche of funding not available elsewhere. We are therefore delighted to see the success of the collaboration between PlaqueTec and the Welch research group to date and look forward to further updates once evaluation via PlaqueTec’s BIOPATTERN trial is concluded.”

Notes

Media contact

Anna Bakewell

Zyme Communications

Tel: +44(0) 7801 098 242

Email: anna.bakewell@zymecommunications.com

About PlaqueTec

PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine.CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients. The Company is based at the world-renowned Babraham Research Campus, Cambridge, UK. Follow PlaqueTec on LinkedIn and Twitter .

About �鶹��Ƶ

�鶹��Ƶ undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The �鶹��Ƶ is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through �鶹��Ƶ Strategic Programme Grants and an �鶹��Ƶ Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.

About Babraham Research Campus

Babraham Research Campus Ltd is responsible for the management and commercial development of the Babraham Research Campus. Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with �鶹��Ƶ, a world‐renowned research organisation which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The aim of the Campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organisations. The Campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

For more information please visit: and follow the Campus on LinkedIn .